WO2006026619A3 - Inhibition of viruses using rnase h inhibitors - Google Patents
Inhibition of viruses using rnase h inhibitors Download PDFInfo
- Publication number
- WO2006026619A3 WO2006026619A3 PCT/US2005/030846 US2005030846W WO2006026619A3 WO 2006026619 A3 WO2006026619 A3 WO 2006026619A3 US 2005030846 W US2005030846 W US 2005030846W WO 2006026619 A3 WO2006026619 A3 WO 2006026619A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rnase
- inhibitors
- viruses
- inhibition
- aminocarbonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005279845A AU2005279845A1 (en) | 2004-08-30 | 2005-08-30 | Inhibition of viruses using RNase H inhibitors |
EP05803872A EP1796662A2 (en) | 2004-08-30 | 2005-08-30 | Inhibition of viruses using rnase h inhibitors |
CA002579089A CA2579089A1 (en) | 2004-08-30 | 2005-08-30 | Inhibition of viruses using rnase h inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60516504P | 2004-08-30 | 2004-08-30 | |
US60/605,165 | 2004-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006026619A2 WO2006026619A2 (en) | 2006-03-09 |
WO2006026619A3 true WO2006026619A3 (en) | 2006-05-04 |
Family
ID=35744862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/030846 WO2006026619A2 (en) | 2004-08-30 | 2005-08-30 | Inhibition of viruses using rnase h inhibitors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1796662A2 (en) |
AU (1) | AU2005279845A1 (en) |
CA (1) | CA2579089A1 (en) |
WO (1) | WO2006026619A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA022521B1 (en) | 2010-04-28 | 2016-01-29 | Астеллас Фарма Инк. | Tetrahydrobenzothiophene compounds, pharmaceutical composition based thereon, use thereof and method for treating hyperphosphatemia |
WO2012167011A1 (en) | 2011-06-02 | 2012-12-06 | Massachusetts Institute Of Technology | Dsrna/dna hybrid genome replication intermediate of metakaryotic stem cells |
JP6020460B2 (en) | 2011-10-27 | 2016-11-02 | アステラス製薬株式会社 | Aminoalkyl-substituted N-thienylbenzamide derivatives |
WO2014179786A1 (en) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Improved honeybee repellents and uses thereof |
WO2014179785A1 (en) * | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Improved honeybee repellents and uses thereof |
EP3562818B1 (en) | 2016-12-29 | 2022-05-18 | ENYO Pharma | Thiophene derivatives as antiviral agents |
EP3612180B1 (en) * | 2017-04-17 | 2023-10-11 | The Regents of the University of California | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a |
US20220000864A1 (en) * | 2018-11-19 | 2022-01-06 | 11949098 Canada Inc. | MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027200A1 (en) * | 1996-01-26 | 1997-07-31 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
WO1998037880A1 (en) * | 1997-02-26 | 1998-09-03 | Ciblex Corporation | Inhibitors of leaderless protein export |
WO1998045298A1 (en) * | 1997-04-10 | 1998-10-15 | Smithkline Beecham Plc | Antiviral agents |
WO2001098290A2 (en) * | 2000-06-19 | 2001-12-27 | Pharmacia Italia S.P.A. | Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
EP1352650A1 (en) * | 2000-12-18 | 2003-10-15 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
WO2004009582A1 (en) * | 2002-07-19 | 2004-01-29 | Pharmacia Corporation | Substituted thiophene carboxamide compounds for the treatment of inflammation |
WO2004032827A2 (en) * | 2002-05-20 | 2004-04-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2004089360A1 (en) * | 2003-04-02 | 2004-10-21 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
WO2005027882A1 (en) * | 2003-09-22 | 2005-03-31 | Bionetworks Gmbh | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
WO2005060711A2 (en) * | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
WO2005072412A2 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
-
2005
- 2005-08-30 CA CA002579089A patent/CA2579089A1/en not_active Abandoned
- 2005-08-30 WO PCT/US2005/030846 patent/WO2006026619A2/en active Application Filing
- 2005-08-30 AU AU2005279845A patent/AU2005279845A1/en not_active Abandoned
- 2005-08-30 EP EP05803872A patent/EP1796662A2/en not_active Withdrawn
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027200A1 (en) * | 1996-01-26 | 1997-07-31 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
WO1998037880A1 (en) * | 1997-02-26 | 1998-09-03 | Ciblex Corporation | Inhibitors of leaderless protein export |
WO1998045298A1 (en) * | 1997-04-10 | 1998-10-15 | Smithkline Beecham Plc | Antiviral agents |
WO2001098290A2 (en) * | 2000-06-19 | 2001-12-27 | Pharmacia Italia S.P.A. | Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
EP1352650A1 (en) * | 2000-12-18 | 2003-10-15 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
WO2004032827A2 (en) * | 2002-05-20 | 2004-04-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2004009582A1 (en) * | 2002-07-19 | 2004-01-29 | Pharmacia Corporation | Substituted thiophene carboxamide compounds for the treatment of inflammation |
WO2004089360A1 (en) * | 2003-04-02 | 2004-10-21 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
WO2005027882A1 (en) * | 2003-09-22 | 2005-03-31 | Bionetworks Gmbh | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
WO2005060711A2 (en) * | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
WO2005072412A2 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
Also Published As
Publication number | Publication date |
---|---|
WO2006026619A2 (en) | 2006-03-09 |
EP1796662A2 (en) | 2007-06-20 |
AU2005279845A1 (en) | 2006-03-09 |
CA2579089A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006026619A3 (en) | Inhibition of viruses using rnase h inhibitors | |
WO2005087731A8 (en) | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | |
EP1924593B8 (en) | Hcv ns3 protease inhibitors | |
WO2005051980A8 (en) | Depeptidized inhibitors of hepatitis c virus ns3 protease | |
WO2006119061A3 (en) | Hcv ns3 protease inhibitors | |
WO2004041201A3 (en) | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases | |
WO2007092645A3 (en) | Novel hcv inhibitor combinations and methods | |
WO2006066079A3 (en) | Pyridazinone compounds | |
WO2008057208A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051514A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051475A3 (en) | Hcv ns3 protease inhibitors | |
WO2007076034A3 (en) | Anti-viral compounds | |
WO2005087725A3 (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
WO2007070556A3 (en) | N-(6-membered aromatic ring)-amido anti-viral compounds | |
CA2473070A1 (en) | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection | |
WO2006081554A3 (en) | Phenyl-substituted pyrrolidones | |
MX2009006880A (en) | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections. | |
DE602005027580D1 (en) | INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS THEREOF WHERE THEY ARE USED | |
WO2007140200A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
WO2007084413A3 (en) | Methods for treating hepatitis c | |
WO2004110351A3 (en) | Heterocyclic compounds for treating hepatitis c virus | |
WO2008115281A3 (en) | Compounds for treating viral infections | |
WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
NO20062146L (en) | Nucleoside compounds for the treatment of viral infections | |
WO2001077091A3 (en) | Ns5b hcv polymerase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005803872 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2579089 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005279845 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005279845 Country of ref document: AU Date of ref document: 20050830 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005279845 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005803872 Country of ref document: EP |